Catalyst Pharmaceuticals

CPRX94

High Quality

$22.05arrow_drop_up1.68%$0.36

High Quality

High Growth

CPRX94

$22.05

arrow_drop_up1.68%$0.36

High Quality

High Growth

Performance History

Key Stats
Open	$22.76
Prev. Close	$22.80
EPS	1.18
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	21.70	23.62
52 Week Range	11.89	24.32

Ratios







EPS	1.18

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc. (CPRX) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for rare neurological disorders. The company's lead product candidate is Firdapse® (amifampridine phosphate), which is currently approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. Firdapse® works by enhancing the release of acetylcholine, a neurotransmitter that plays a crucial role in muscle contraction.

Catalyst Pharmaceuticals Inc. recently announced positive top-line results from a Phase 3 trial evaluating Firdapse® in pediatric patients with LEMS. The study met its primary endpoint, demonstrating a statistically significant improvement in the Quantitative Myasthenia Gravis (QMG) score compared to placebo. This data further supports the potential of Firdapse® as a treatment option for a broader patient population beyond adults with LEMS.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Patrick J. McEnany
Headquarters: Coral Gables
Employees: 82
Exchange: NASDAQ

add Catalyst Pharmaceuticals to watchlist

Keep an eye on Catalyst Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Catalyst Pharmaceuticals 's (CPRX) price per share?

The current price per share for Catalyst Pharmaceuticals (CPRX) is $22.06. The stock has seen a price change of $0.37 recently, indicating a 1.69% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Catalyst Pharmaceuticals (CPRX)?

For Catalyst Pharmaceuticals (CPRX), the 52-week high is $24.33, which is 10.31% from the current price. The 52-week low is $11.89, the current price is 85.5% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Catalyst Pharmaceuticals (CPRX) a growth stock?

Catalyst Pharmaceuticals (CPRX) has shown an average price growth of -3.55% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Catalyst Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Catalyst Pharmaceuticals (CPRX) stock price performance year to date (YTD)?

As of the latest data, Catalyst Pharmaceuticals (CPRX) has a year-to-date price change of 28.91%. Over the past month, the stock has experienced a price change of 6.86%. Over the last three months, the change has been 14.64%. Over the past six months, the figure is 33.75%. Looking at a longer horizon, the five-year price change stands at 369.28%.

help

Is Catalyst Pharmaceuticals (CPRX) a profitable company?

Catalyst Pharmaceuticals (CPRX) has a net income of $71.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 78.77% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 39.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $398.2M, with a revenue growth rate of 85.9%, providing insight into the company's sales performance and growth. The gross profit is $313.67M. Operating income is noted at $86.81M. Furthermore, the EBITDA is $211.94M.

help

What is the market capitalization of Catalyst Pharmaceuticals (CPRX)?

Catalyst Pharmaceuticals (CPRX) has a market capitalization of $2.59B. The average daily trading volume is 22.17, indicating the stock's liquidity and investor engagement.